These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 12497543

  • 21. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
    West P, Schmiedeskamp M, Neeley H, Oberholzer J, Benedetti E, Kaplan B.
    Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
    [Abstract] [Full Text] [Related]

  • 22. Cytomegalovirus infections in renal, heart, heart-lung and liver transplantation.
    Pollard RB.
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S97-102. PubMed ID: 2456512
    [Abstract] [Full Text] [Related]

  • 23. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J, Casper K, Smallwood G, Stieber A, Fasola C, Lehneman J, Heffron T.
    Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
    [Abstract] [Full Text] [Related]

  • 24. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 25. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C, LeBlanc MH, Boivin G.
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [Abstract] [Full Text] [Related]

  • 26. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease.
    Humar A, Kumar D, Boivin G, Caliendo AM.
    J Infect Dis; 2002 Sep 15; 186(6):829-33. PubMed ID: 12198618
    [Abstract] [Full Text] [Related]

  • 27. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence.
    Singh N.
    Clin Infect Dis; 2005 Mar 01; 40(5):704-8. PubMed ID: 15714416
    [No Abstract] [Full Text] [Related]

  • 28. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.
    Fica A, Cervera C, Pérez N, Marcos MA, Ramírez J, Linares L, Soto G, Navasa M, Cofan F, Ricart MJ, Pérez-Villa F, Pumarola T, Moreno A.
    Transpl Infect Dis; 2007 Sep 01; 9(3):203-10. PubMed ID: 17511827
    [Abstract] [Full Text] [Related]

  • 29. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G, Boucher HW.
    Clin Infect Dis; 2008 Sep 01; 47(5):702-11. PubMed ID: 18652557
    [Abstract] [Full Text] [Related]

  • 30. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease.
    Manuel O, Asberg A, Pang X, Rollag H, Emery VC, Preiksaitis JK, Kumar D, Pescovitz MD, Bignamini AA, Hartmann A, Jardine AG, Humar A.
    Clin Infect Dis; 2009 Oct 15; 49(8):1160-6. PubMed ID: 19751151
    [Abstract] [Full Text] [Related]

  • 31. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B, Thomas CD, Radovancevic R, Frazier OH, Radovancevic B.
    J Heart Lung Transplant; 2004 Apr 15; 23(4):461-5. PubMed ID: 15063406
    [Abstract] [Full Text] [Related]

  • 32. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ, Busuttil RW.
    Transplantation; 2004 Jan 27; 77(2):305-8. PubMed ID: 14742998
    [Abstract] [Full Text] [Related]

  • 33. Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors.
    Sabé N, González-Costello J, Rama I, Niubó J, Bodro M, Roca J, Cruzado JM, Manito N, Carratalà J.
    Transpl Int; 2012 Jul 27; 25(7):e78-82. PubMed ID: 22574951
    [Abstract] [Full Text] [Related]

  • 34. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients.
    Ozaki KS, Câmara NO, Nogueira E, Pereira MG, Granato C, Melaragno C, Camargo LF, Pacheco-Silva A.
    Clin Transplant; 2007 Jul 27; 21(5):675-80. PubMed ID: 17845644
    [Abstract] [Full Text] [Related]

  • 35. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ, Busuttil RW.
    Transplantation; 2003 Jan 27; 75(2):229-33. PubMed ID: 12548129
    [Abstract] [Full Text] [Related]

  • 36. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Jan 27; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 37. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
    Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, Ives J, Hartmann A, Humar A.
    Antivir Ther; 2009 Jan 27; 14(5):697-704. PubMed ID: 19704173
    [Abstract] [Full Text] [Related]

  • 38. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
    Bruminhent J, Rotjanapan P, Watcharananan SP.
    Transplant Proc; 2017 Jun 27; 49(5):1048-1052. PubMed ID: 28583524
    [Abstract] [Full Text] [Related]

  • 39. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.
    García-Martínez J, Folgueira L, Delgado R, Hernando S, Prieto C, Aguado JM, Otero JR.
    Transpl Infect Dis; 2008 Apr 27; 10(2):123-8. PubMed ID: 17605746
    [Abstract] [Full Text] [Related]

  • 40. Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
    Paya CV.
    Clin Infect Dis; 2001 Feb 15; 32(4):596-603. PubMed ID: 11181123
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.